5-Amino-1MQ vs Cagrilintide

Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is fat loss and metabolic health. On this site's goal weighting — an editorial priority score, not a measure of effect size — 5-Amino-1MQ rates 4/5 for fat loss and Cagrilintide rates 4/5. Outside that overlap only Cagrilintide goes further, carrying weight for appetite control; 5-Amino-1MQ's declared goals stop at the overlap.

This is the part that decides most of it. Cagrilintide has controlled human trials behind it, without an approval — investigational; standalone long-term data does not exist yet. 5-Amino-1MQ has animal and cell data only, and no controlled human dosing trials — dose figures are extrapolated from vendor and community practice. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

5-Amino-1MQ is taken by mouth; Cagrilintide is a subcutaneous injection. That is the difference most people actually feel: Cagrilintide means reconstituting a vial and injecting; 5-Amino-1MQ does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Cagrilintide has a characterized half-life of 7.5 days; 5-Amino-1MQ does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.

One of these has an end date and the other does not: 5-Amino-1MQ runs 12 weeks, Cagrilintide runs no fixed cycle. An open-ended compound is a standing commitment, not a course you finish. Cagrilintide also escalates through a titration schedule rather than holding one dose, so its first weeks are not its steady state.

5-Amino-1MQ is rated intermediate here and Cagrilintide advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.